Danish firm Lundbeck (LUND: CO) and Japan’s Otsuka Pharmaceutical (TYO: 4578) have secured European approval for a new formulation of Abilify Maintena (aripiprazole).
The 960mg dose of aripiprazole is designed to be taken every two months, providing a patient-friendly option for the maintenance treatment of schizophrenia in adults.
Further development of the blockbuster drug comes as the collaborators face a significant market shift, with current exclusivity for the compound coming to an end.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze